Volume 22, Number 9—September 2016
Letter
Community-Acquired Clostridium difficile Infection, Queensland, Australia
Table
Medication exposure | Odds ratio (95% credible interval) | p value | Holm-adjusted p value |
---|---|---|---|
Drugs for acid-related disorders | 1.052 (0.943–1.163) | 0.348 | 0.819 |
Drugs for constipation | 1.056 (0.963–1.151) | 0.235 | 0.781 |
Antidiarrheal drugs | 1.106 (0.994–1.218) | 0.051 | 0.379 |
Antithrombotic drugs | 1.073 (0.955–1.197) | 0.224 | 0.781 |
Corticosteroids for systemic use | 1.043 (0.952–1.133) | 0.348 | 0.819 |
Antibacterial drugs for systemic use | 1.083 (0.990–1.174) | 0.067 | 0.425 |
Antimycotic drugs for systemic use | 1.035 (0.944–1.126) | 0.454 | 0.819 |
Antimicrobial drugs for mycobacterial infections | 1.089 (1.023–1.155) | 0.006 | 0.063 |
Anti-inflammatory drugs | 1.070 (0.970–1.170) | 0.158 | 0.700 |
Antiprotozoal drugs | 1.037 (0.953–1.123) | 0.394 | 0.819 |
Anthelminthic drugs | 1.068 (1.008–1.127) | 0.021 | 0.189 |
Page created: August 16, 2016
Page updated: August 16, 2016
Page reviewed: August 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.